A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)

Trial Profile

A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Verubecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms EPOCH
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 This trial has been completed in Portugal (end date: 14 Apr 2017).
    • 11 May 2017 This trial has been completed in Austria (end date: 14 Apr 2017).
    • 09 May 2017 This trial has been completed in Netherlands and Hungary (end date: 14 Apr 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top